Six Months Clinical and Echocardiographic Outcome of Angiotensin Receptor-Neprilysin Inhibitor (ARNI) LCZ696 Therapy in Heart Failure Patients With Reduced Ejection Fraction (HFrEF)
Latest Information Update: 17 Jan 2020
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Therapeutic Use
Most Recent Events
- 14 Jan 2020 Status changed from recruiting to completed.
- 06 Jun 2019 Planned End Date changed from 1 Jun 2019 to 1 Sep 2019.
- 06 Jun 2019 Planned primary completion date changed from 1 May 2019 to 1 Aug 2019.